AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn reported in the same period last year. The company's total revenue surged by 19% to $12.68bn in Q1 2024. This was driven by an 18% increase in product sales and sustained growth in alliance revenue from partnered medicines.